The field of sarcoma treatment is currently undergoing a remarkable transformation with the development of cutting-edge therapeutic strategies and promising drugs. This article aims to provide an in-depth overview of these emerging treatment options and highlight key findings from recent research, shedding light on the potential breakthroughs in sarcoma management.
Q1: Thank you for accepting this interview. Can you share your feelings about your participation? What types of new drugs impressed you?
A: In the special symposium we will discuss several different mechanisms and potential new drugs.
And there are many and perhaps too many to discuss in this interview. But what is emerging is, for example, the treatment with MDM -2 inhibitors for several sarcomotor subtypes, of which the most common is the differentiated liposarcomas.
So that’s one avenue that has not been explored too much recently and is a focus for over the last years. What has also been seen is that there are several new or two new phase one trials in gastrointestinal stromal tumor that was presented today, also with promising results which might benefit patients in the not too distant future.
Thank you very much. The second question is, could you introduce some of the new therapeutic strategies of drugs and mechanism that are currently being exported or showing promise? Yeah, I mentioned the two phase one studies that were presented today.
In one of them there is a combination of an HSP -90 inhibitor and imatinib, a study performed in Japan, which had interesting results. And then coming back also to the MDM -2 inhibitor, that will be an interesting field to follow.
And the final thing is that there are several studies being presented in sarcomas with immunotherapy and immunotherapy combinations. And there I think it’s a lot of things we do not understand fully at the moment, but I believe we will see important and interesting results there soon.
Q2: Thank you very much. The last question is about any highlights or ideas you can share during this session for patients and doctors that can bring international response for them?
A: Perhaps the most important presentation in this meeting is the late -breaking data of a phase 3 study in the differentiated liposarcoma of an MDM2 inhibitor compared with trabecutin.
Unfortunately, this study in Leipzig -Arkhamma was negative. So there is no statistically significant benefit of the MDM2 inhibitor compared to Trebekhtheden, which was disappointing and we’ll see those results tomorrow morning.
